Drug Profile

EBT 101

Alternative Names: EBT-101

Latest Information Update: 14 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Temple University; University of California at Berkeley
Developer Excision BioTherapeutics
Class Antiretrovirals; Gene therapies
Mechanism of Action Gene expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II HIV-1 infections

Most Recent Events

14 Nov 2024 Excision BioTherapeutics completes a phase I/II clinical trials in HIV-1 infections (Adjunctive treatment) in USA (IV) (NCT05144386)
13 May 2024 Updated adverse events data from a phase I/II trial in HIV-1 patients released by Excision BioTherapeutics
25 Oct 2023 Interim safety and pharmacokinetics data from the phase I/II trial in HIV-1 patients released by Excision BioTherapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com